Transparency and acknowledgements

 Operating programmeAmount% on category% on total income
Grants342.900  
 Astra Zeneca30.0008,75%2,96%
 BI30.0008,75%2,96%
 Chiesi30.0008,75%2,96%
 Sanofi Genzyme30.0008,75%2,96%
 Regeneron30.0008,75%2,96%
 Roche30.0008,75%2,96%
 OMPharma30.0008,75%2,96%
 Pfizer30.0008,75%2,96%
 DBV Technologies30.0008,75%2,96%
 Almirall42.90012,51%4,23%
 Menarini30.0008,75%2,96%
Honoraria for Advisors   
 Honoraria for Advisors6.995,00 0,69%
Membership Fees   
 Membership fees13.030,00 1,28%
Deferred income 2024 for 2025 EFA Core activities-130.500  
Project programme   
EFA projects567.960  
 Atopic Eczema Burden VI WAED Sanofi/Regeneron92.70016,32%9,14%
 Atopic Eczema Burden VI WAED Deferred income from 202341.0007,22%4,04%
 COPD Beyond Care Astra Zeneca35.0006,16%3,45%
 COPD Beyond Care Roche35.0006,16%3,45%
 COPD Beyond Care Sanofi/Regeneron25.0004,40%2,46%
 COPD Beyond Care Deferred Income from 202337.7606,65%3,72%
 Breathe BY 2030 Astra Zeneca57.00010,04%5,62%
 Breathe BY 2030 Roche40.0007,04%3,94%
 Breathe BY 2030 Sanofi/Regeneron50.0008,80%4,93%
 Breathe BY 2030 Deferred Income from 202328.0004,93%2,76%
 About Asthma Astra Zeneca40.0007,04%3,94%
 About Asthma Sanofi/Regeneron25.0004,40%2,46%
 About Asthma Deferred Income from 202312.5002,20%1,23%
 Capacity Building Deferred Income from 202321.0003,70%2,07%
 AE Catalytic Project Deferred Income from 202323.0004,05%2,27%
 Interest Group Deferred Income from 20235.0000,88%0,49%
Deferred income 2024 to EFA Projects 2025-10.000  
EU projects73.695,19  
 3TR4.032,465,47%0,40%
 ImmUniverse5.705,127,74%0,56%
 TOLIFE13.312,9918,06%1,31%
 SynAir-G46.488,5963,08%4,58%
 LH4L4.156,035,64%0,41%